Compound 2f (SARM)

Compound 2f (SARM)
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 4-[(2S,3S)-2-ethyl-3-hydroxy-5-oxopyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile;
CAS Number	1114546-03-0;
PubChem CID	59556974;
ChemSpider	59053603;
ChEMBL	ChEMBL4088914;
Chemical and physical data
Formula	C14H13F3N2O2
Molar mass	298.265 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H]1[C@H](CC(=O)N1C2=CC(=C(C=C2)C#N)C(F)(F)F)O;
	InChI InChI=1S/C14H13F3N2O2/c1-2-11-12(20)6-13(21)19(11)9-4-3-8(7-18)10(5-9)14(15,16)17/h3-5,11-12,20H,2,6H2,1H3/t11-,12-/m0/s1; Key:LJQBTMVNFWIQQC-RYUDHWBXSA-N;

Compound 2f (SARM) is a drug which acts as a selective androgen receptor modulator (SARM), originally developed by Takeda Pharmaceutical for the treatment of prostate cancer. It is a potent but tissue specific androgen agonist with an EC₅₀ of 4.7nM, producing anabolic effects on muscles and in the central nervous system but with little effect on the prostate gland, and inducing sexual behaviour in animal studies.^[1]^[2]^[3]